Hagop M. Kantarjian, Susan O'Brien, Xuelin Huang, Guillermo Garcia-Manero, Farhad Ravandi, Jorge Cortes, Jianqin Shan, Jan Davisson, Carlos E. Bueso-Ramos and Jean-Pierre Issa Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome Cancer 109
Version of Record online: 21 FEB 2007 | DOI: 10.1002/cncr.22508
The authors compared the outcome of decitabine therapy in 115 patients with higher risk myelodysplastic syndrome with contemporary historic experience with intensive chemotherapy in similar patients. Complete response rates were comparable with the 2 strategies, but early mortality was significantly higher with intensive chemotherapy. Survival was significantly better with decitabine compared with intensive chemotherapy, whether matched historic controls were used, or whether the total experience was analyzed, with chemotherapy incorporated (decitabine vs intensive chemotherapy) in a multivariate analysis of factors for survival.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field